10 Best Russell 2000 Stocks to Invest in According to Analysts

5. Insmed Incorporated (NASDAQ:INSM)

Upside Potential: 23.32%

Stock Price as of January 16: $71.47

Number of Hedge Fund Investors: 25

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focused on developing therapies for rare diseases. The company’s lead product, Arikayce, treats patients with refractory nontuberculous mycobacterial lung infections. Insmed Incorporated (NASDAQ:INSM) is also advancing other pipeline candidates targeting pulmonary and orphan diseases.

Insmed Incorporated (NASDAQ:INSM) is focusing on broadening Arikayce’s market reach by expanding its sales force and optimizing its distribution channels to ensure that the treatment is accessible to patients in both academic centers and community pulmonologist offices. Additionally, Insmed Incorporated (NASDAQ:INSM) is actively pursuing label expansion for Arikayce. The Phase 2 ENCORE study, which is evaluating Arikayce in a broader patient population, has exceeded its target enrollment, ensuring that the study is well-powered for both U.S. and Japanese regulatory requirements. Insmed Incorporated (NASDAQ:INSM) plans to meet with the FDA to discuss the possibility of an accelerated filing, which could expedite the approval process and further enhance  Arikayce’s market potential.

Furthermore, Insmed Incorporated (NASDAQ:INSM) is also advancing the potential launch of brensocatib, a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor, for the treatment of bronchiectasis. The company has nearly tripled its U.S. sales force to 184 representatives and has strategically deployed across the country based on claims data to ensure that they can effectively reach and educate healthcare providers about the benefits of brensocatib. Insmed Incorporated (NASDAQ:INSM) is expecting a decision from the FDA in the first quarter of 2025. The company is also exploring additional indications for brensocatib, including chronic rhinosinusitis without nasal polyps (CRSsNP) and hidradenitis suppurativa (HS), both of which are in Phase 2 clinical trials.